5The Rotterdam ESHRE/ASRM- Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long - term health risks related to polycystic ovary syndrome [J]. Hum Reprod, 2004, 19 (1) : 41.
6Azziz R, Carmina E, Dewailly D et al. Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline [J]. J Clin Endocrinol Metab, 2006, 91 (11): 4237.
7Falsetti L, Gambera A, Tisi G. Efficacy of the combination ethinyl oestradiol and cyproterone acetate on endocrine, clinical and ultrasono- graphic profile in polycystic ovarian syndrome[J]. Hum Repmd, 2001, 16 (1): 36.
8Cagnacci A, Paoletti AM, Renzi A. Glucose metabolism and insulin resistance on women with polycystic ovary syndrome during therapy with oral contraceptives containing cyproterone acetate or desogestrel [J]. Clin Endocrinol Metab, 2003, 88 (8) : 3621.
9Azziz R, Woods KS, Reyna R, et al. The prevalence and features of the polycystic ovary syndrome in an unselected population [ J ]. J Clin Endocrinol Metab, 2004, 89(6) :2745 -2749.
10Asuncion M, Cairo RM, San Millan JL, et al. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Cauca- sian women from Spain [ J]. J Clin Endocrinol Metab, 2000, 85 (7) : 2434 - 2438.
